Quality of life is maintained with ixazomib maintenance in post‐transplant newly diagnosed multiple myeloma: The TOURMALINE‐MM3 trial — Fredrik Schjesvold (2019) | RDL Network
Quality of life is maintained with ixazomib maintenance in post‐transplant newly diagnosed multiple myeloma: The TOURMALINE‐MM3 trial
Article 2019 en
Authors
FS
Fredrik Schjesvold
HG
Hartmut Goldschmidt
VM
Vladimír Maisnar
Abstract
1 min read
In addition to improvement in progression-free survival with ixazomib, HRQoL was maintained in both arms. Active treatment with ixazomib did not have an adverse impact on HRQoL.
Fredrik Schjesvold, Hartmut Goldschmidt, Vladimír Maisnar, Niels Abildgaard, Philip Rowlings, Dawn Odom, Ari Gnanasakthy, Kaveri Suryanarayan, Lorna Cain, Dorothy Romanus, S. Vincent Rajkumar, Meletios A Dimopoulos
Martin Kaiser, Meral Beksaç, Nina Gulbrandsen, Fredrik Schjesvold, Roman Hájek, Philippe Moreau, Felipe de Arriba, María‐Victoria Mateos, Sharon West, Andrew Spencer, S. Vincent Rajkumar, Kaveri Suryanarayan, Michael Czorniak, Cong Li, Zhaoyang Teng, Richard Labotka, Meletios A Dimopoulos
Meletios A Dimopoulos, Hartmut Goldschmidt, Vladimír Maisnar, Ivan Špıčka, Niels Abildgaard, Philip Rowlings, S. Vincent Rajkumar, Lauren E. Cain, Dorothy Romanus, Kaveri Suryanarayan, Dawn Odom, Ari Gnanasakthy, Fredrik Schjesvold
Meletios A Dimopoulos, Ivan Špıčka, Hang Quach, Albert Oriol, Roman Hájek, Mamta Garg, Meral Beksaç, Sara Bringhen, Eirini Katodritou, Wee Joo Chng, Xavier Leleu, Shinsuke Iida, María‐Victoria Mateos, Gareth J. Morgan, Alexander Vorog, Richard Labotka, Bingxia Wang, Antonio Palumbo, Sagar Lonial
Discussion(0)
No comments yet. Be the first to comment.